Trends and risk factors of SARS-CoV-2 infection in asymptomatic blood donors.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: American Association Of Blood Banks Country of Publication: United States NLM ID: 0417360 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1537-2995 (Electronic) Linking ISSN: 00411132 NLM ISO Abbreviation: Transfusion Subsets: MEDLINE
    • Publication Information:
      Original Publication: Arlington, Va. : American Association Of Blood Banks
    • Subject Terms:
      Asymptomatic Infections* ; Blood Donors* ; COVID-19*/transmission; Antibodies, Viral/blood ; Humans ; Immunoglobulin G/blood ; Immunoglobulin M/blood ; Prospective Studies ; Risk Factors ; SARS-CoV-2 ; Seroepidemiologic Studies
    • Abstract:
      Background: A large proportion of SARS-CoV-2-infected individuals does not develop severe symptoms. Serological tests help in evaluating the spread of infection and disease immunization. The aim of this study was to prospectively examine the trends and risk factors of SARS-CoV-2 infection in blood donors.
      Study Design and Methods: We screened 8798 asymptomatic donors presenting in Milan from July 2020 to February 2021 (10,680 presentations) before the vaccination campaign for anti-nucleoprotein (NP) antibodies, and for anti-spike receptor-binding domain (RBD) antibodies and nasopharyngeal swab PCR in those who tested positive.
      Results: The prevalence of anti-NP+/RBD+ tests increased progressively with time up to ~15% (p < .0001), preceded by a peak of PCR+ tests. Anti-RBD titers were higher in anti-NP IgG+/IgM+ than in IgG+/IgM- individuals and in those with a history of infection (p < .0001); of these 197/630 (31.2%) displayed high titers (>80 AU/ml). Anti-RBD titers declined during follow-up, depending on baseline titers (p < .0001) and time (p = .025). Risk factors for seroconversion were a later presentation date and non-O ABO blood group (p < .001). A positive PCR was detected in 0.7% of participants in the absence of SARS-CoV-2 viremia.
      Conclusions: During the second wave of SARS-CoV-2 infection in Northern Italy, we detected an increase in seroprevalence in healthy blood donors from ~4% to ~15%, with a trend paralleling that observed in the general population. Seroconversion was more frequent in carriers of non-O blood groups. The persistence of anti-RBD antibodies was short-lived.
      (© 2021 The Authors. Transfusion published by Wiley Periodicals LLC on behalf of AABB.)
    • References:
      J Clin Med. 2020 Oct 01;9(10):. (PMID: 33019628)
      N Engl J Med. 2020 Oct 15;383(16):1522-1534. (PMID: 32558485)
      Blood. 2021 Mar 25;137(12):1573-1581. (PMID: 33202419)
      Blood Transfus. 2021 May;19(3):181-189. (PMID: 33539289)
      Nature. 2021 Jul 8;:. (PMID: 34237774)
      Transfusion. 2020 Dec;60(12):3067-3070. (PMID: 33009662)
      Lancet Infect Dis. 2020 May;20(5):533-534. (PMID: 32087114)
      JAMA. 2021 Oct 12;326(14):1400-1409. (PMID: 34473201)
      Transfusion. 2021 Dec;61(12):3381-3389. (PMID: 34647620)
      Clin Microbiol Infect. 2021 Apr;27(4):511-519. (PMID: 33484843)
      J Clin Microbiol. 2020 Aug 24;58(9):. (PMID: 32580948)
      Int J Infect Dis. 2021 Mar;104:458-464. (PMID: 33444755)
      Vox Sang. 2021 Sep;116(8):849-861. (PMID: 33578447)
      Nature. 2020 Aug;584(7821):425-429. (PMID: 32604404)
      Acta Haematol. 2021;144(5):580-584. (PMID: 33878755)
      JAMA. 2020 Apr 28;323(16):1574-1581. (PMID: 32250385)
      N Engl J Med. 2020 Feb 20;382(8):727-733. (PMID: 31978945)
      Lancet Haematol. 2020 Oct;7(10):e756-e764. (PMID: 32628911)
      PLoS Med. 2020 Sep 22;17(9):e1003346. (PMID: 32960881)
      J Med Virol. 2021 Apr;93(4):2160-2167. (PMID: 33064340)
      Blood Transfus. 2021 Jul;19(4):277-280. (PMID: 34059190)
    • Grant Information:
      Ricerca Corrente Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico; Fondazione Pesenti, Bergamo, Italy; IN-IT-989-5790 Gilead Sciences; LITMUS - 777377 Horizon 2020 Framework Programme; REVEAL - 101016726 Horizon 2020 Framework Programme; RF-2016-02364358 Ricerca Finalizzata Ministero della Salute; RC100017A Fondazione IRCCS Ca' Granda core COVID-19 Biobank; Fondazione IRCCS Ca' Granda "Liver BIBLE" PR-0391; CV PREVITAL - strategie di prevenzione primaria cardiovascolare primaria nella popolazione italiana, Italian Ministry of Health - Rete Cardiologica IRCCS
    • Contributed Indexing:
      Keywords: ABO blood group; COVID-19; anemia; epidemiology; ferritin
    • Accession Number:
      0 (Antibodies, Viral)
      0 (Immunoglobulin G)
      0 (Immunoglobulin M)
    • Publication Date:
      Date Created: 20211014 Date Completed: 20220106 Latest Revision: 20220106
    • Publication Date:
      20240628
    • Accession Number:
      PMC8661834
    • Accession Number:
      10.1111/trf.16693
    • Accession Number:
      34647620